Literature DB >> 18566583

Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines.

R Pudil1, J M Horacek, A Strasova, L Jebavy, J Vojacek.   

Abstract

AIM: To analyze the very early changes of diastolic LV function during and after chemotherapy (CT) in patients with newly diagnosed acute leukemia.
METHODS: 26 patients with acute leukemia have been studied. The cardiac echo evaluation was performed at the baseline (before CT), after the first CT (mean cumulative anthracyclines dose 136.3-/+28.3 mg m(-2)), after the last CT (mean cumulative anthracyclines dose 464.3-/+117.5 mg m(-2)) and circa 6 months after the completion of CT.
RESULTS: We found a significant decrease in LVEF (65.3-/+4.5' vs 60.2-/+5.7', p<0.01), the fractional shortening of the LV (34.8-/+3.7', vs 29.5-/+5.0', p<0.01), but the mitral flow rapid filling velocity (E-wave) was not changed (0.74-/+0.18 ms(-1), vs 0.67-/+0.17 ms(-1), p ns), and atrial filling velocity (A-wave) increased (0.66-/+0.15 ms(-1) vs 0.78-/+0.18 ms(-1), p<0.01). E/A ratio significantly decreased (1.18-/+0.35 vs 0.89-/+0.27, p<0.01). IVRT increased (71.5-/+11.6 ms vs 84.0-/+11.6 ms, p<0.01). DT E-wave velocity increased (162.3-/+25.8 ms vs 206.7-/+25.5 ms, p<0.01). After the first CT, the signs of LV diastolic dysfunction were detected in 5 (19.2') patients. 6 months after the last CT, two of these patients (7.7') developed LV systolic dysfunction with the clinical symptoms of heart failure. Six months after the last CT, 12 (46.2') patients developed the signs of LV diastolic dysfunction.
CONCLUSION: Chemotherapy can induce early changes of diastolic left ventricular function. We consider using Doppler echocardiography as the election tool not only for baseline cardiologic screening but also for the monitoring of the earliest subclinical signs of cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566583

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  7 in total

Review 1.  Cardiotoxicity due to chemotherapy: role of cardiac imaging.

Authors:  Frédéric Poulin; Paaladinesh Thavendiranathan
Journal:  Curr Cardiol Rep       Date:  2015-03       Impact factor: 2.931

2.  Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.

Authors:  Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Victor Cohen; Sucheta Gosavi; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie
Journal:  Am J Cardiol       Date:  2011-03-02       Impact factor: 2.778

3.  Position Statement on Indications of Echocardiography in Adults - 2019.

Authors:  Silvio Henrique Barberato; Minna Moreira Dias Romano; Adenalva Lima de Souza Beck; Ana Clara Tude Rodrigues; André Luiz Cerqueira de Almeida; Bruna Morhy Borges Leal Assunção; Eliza de Almeida Gripp; Fabio Villaça Guimarães Filho; Henry Abensur; José Maria Del Castillo; Marcelo Haertel Miglioranza; Marcelo Luiz Campos Vieira; Márcio Vinicius Lins de Barros; Maria do Carmo Pereira Nunes; Maria Estefania Bosco Otto; Renato de Aguiar Hortegal; Rodrigo Bellio de Mattos Barretto; Thais Harada Campos; Vicente Nicoliello de Siqueira; Samira Saady Morhy
Journal:  Arq Bras Cardiol       Date:  2019-08-08       Impact factor: 2.000

Review 4.  Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.

Authors:  Wendy J Bottinor; Christopher K Migliore; Carrie A Lenneman; Marcus F Stoddard
Journal:  Curr Cardiol Rep       Date:  2016-10       Impact factor: 2.931

5.  Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.

Authors:  John D Groarke; Toni K Choueiri; David Slosky; Susan Cheng; Javid Moslehi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09

6.  Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.

Authors:  Gaetano Corazzelli; Ferdinando Frigeri; Manuela Arcamone; Anna Lucania; Maria Rosariavilla; Emanuela Morelli; Alfonso Amore; Gaetana Capobianco; Antonietta Caronna; Cristina Becchimanzi; Francesco Volzone; Gianpaolo Marcacci; Filippo Russo; Rosaria De Filippi; Lucia Mastrullo; Antonio Pinto
Journal:  Br J Haematol       Date:  2011-06-28       Impact factor: 6.998

7.  Cardiotoxicity of cancer therapeutics: current issues in screening, prevention, and therapy.

Authors:  Richard J Sheppard; Jenna Berger; Igal A Sebag
Journal:  Front Pharmacol       Date:  2013-03-12       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.